BACKGROUND: Prostate cancer is an illness with a high incidence, especially among older men. The choice of a treatment option among men above 75 years is, however, not clear. Radical prostatectomy in this age group is connected with a relatively high morbidity. A further possibility of curative treatment is radiotherapy which can be administered in the form of external beam or in combination with high dose rate (HDR) brachytherapy. AIM: The aim of our work was to evaluate how HDR brachytherapy is tolerated among men older than 75 and how associated diseases can influence the tolerance to this treatment. Of interest to us were the treatment results and mortality from other diseases. MATERIALS AND METHODS: We analyzed a sample of 20 men above 75 years old (median 77 years) who were undergoing treatment by a combination of external radiotherapy and brachytherapy. Sixteen (80%) of them had prostate cancer with an intermediate and high risk of recurrence, four had low risk prostate cancer. Most patients, 14 (70%), had less than two comorbidities. RESULTS: The median observation period was 57 months. No perioperative complications were recorded. Acute genitourinary toxicity (GU) to a maximum grade of 1-2 manifested in 60% of cases. Acute gastrointestinal toxicity (GIT) was observed only at grade 1 and in 25% of cases. Late GU toxicity occurred in 35% of patients, with only one showing grade 3; late GIT toxicity was recorded at grade 1 only in 3 patients (15%). 70% of the men lived longer than 3 years after treatment, at present, 50% lived more than 5 years. Long-term biochemical remission was achieved in 18 patients (90%). CONCLUSIONS: HDR BRT is possible and well-tolerated in older men above 75 years in good condition and without serious intercurrence. Well-selected older patients with higher-risk tumours and without serious comorbidities undoubtedly benefit from radical treatment when compared with watchful waiting.

Cancer Centre Department of Radiotherapy and Oncology Nový Jičín Czech Republic

Cancer Centre Department of Radiotherapy and Oncology Nový Jičín Czech Republic ; Medical Faculty Ostrava University Czech Republic

See more in PubMed

Cardia J., Calçada C., Pereira H. Treatment of lung cancer in the elderly: influence of comorbidity on toxicity and survival. Rep Pract Oncol Radiother. 2011;16(2):45–48. PubMed PMC

Alibhai S.M., Leach M., Warde P. Major 30-day complications after radical radiotherapy: a population-based analysis and comparison with surgery. Cancer. 2009;115(2):293–302. PubMed

Trinh QD, Schmitges J, Sun M, et al. Open radical prostatectomy in the elderly: a case for concern? BJU Int, in press. PubMed

Borrusch H., Müller G., Otto U. Urinary incontinence after radical prostatectomy: do older patients have an increased risk? Urologe A. 2011;50(4):457–461. PubMed

Shikanov S., Desai V., Razmaria A., Zagaja G.P., Shalhav A.L. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol. 2010;183(5):1803–1807. PubMed

Xylinas E., Ploussard G., Paul A. Laparoscopic radical prostatectomy in the elderly (>75 years old): oncological and functional results. Prog Urol. 2010;20(2):116–120. PubMed

Tarragón Gabarró S., Lorente Garín J.A., del Canto Aguirre M. Perioperative morbidity of radical prostatectomy in patients over 70 years of age. Actas Urol Esp. 2009;33(9):960–964. PubMed

Froehner M, Hentschel C, Koch R, Litz RJ, Hakenberg OW, Wirth MP. Which comorbidity classification best fits elderly candidates for radical prostatectomy? Urol Oncol, in press. PubMed

Pollack A., Zagars G.K., Starkschall G. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–1105. PubMed

Zelefsky M.J., Leibel S.A., Gaudin P.B. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41(3):491–500. PubMed

Valicenti R., Lu J., Pilepich M. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18(14):2740–2746. PubMed

Kupelian P., Kuban D., Thames H. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61(2):415–419. PubMed

Droz J.P., Balducci L., Bolla M. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462–469. PubMed PMC

Roberts C.B., Albertsen P.C., Shao Y.H. Patterns and correlates of prostate cancer treatment in older men. Am J Med. 2011;124(3):235–243. PubMed PMC

Konety B.R., Cowan J.E., Carroll P.R., CaPSURE Investigators Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179(5):1797–1803. discussion 1803. PubMed

Hayes J.H., Ollendorf D.A., Pearson S.D. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373–2380. PubMed PMC

Saigal C.S., Gore J.L., Krupski T.L. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–1500. PubMed

Hamstra DA, Bae K, Pilepich MV, et al. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of Radiation Therapy Oncology Group Trials. Int J Radiat Oncol Biol Phys, in press. PubMed PMC

Alibhai S.M., Naglie G., Nam R., Trachtenberg J., Krahn M.D. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21(17):3318–3327. PubMed

Chen A.B., D’Amico A.V., Neville B.A., Earle C.C. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298–5304. PubMed

Cancer in the elderly